Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: a single center, retrospective, observational study

Background Proteinuria is a common adverse event observed during treatment with antivascular endothelial growth factor (VEGF) antibodies. Proteinuria is a risk factor for renal dysfunction and cardiovascular complications in patients with chronic kidney disease. However, the association between anti...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2024-04, Vol.29 (4), p.398-406
Main Authors: Kataoka, Shigeki, Nishikawa, Yoshitaka, Funakoshi, Taro, Horimatsu, Takahiro, Sakuragi, Minoru, Uchino, Eiichiro, Hiragi, Shusuke, Yamamoto, Shinya, Sakai, Kaoru, Matsubara, Takeshi, Yanagita, Motoko, Muto, Manabu
Format: Article
Language:English
Subjects:
Bevacizumab
Cancer Research
Kidney diseases
Medicine
Medicine & Public Health
Monoclonal antibodies
Observational studies
Oncology
Original Article
Patients
Proteinuria
Renal function
Risk factors
Surgical Oncology
Targeted cancer therapy
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Proteinuria is a common adverse event observed during treatment with antivascular endothelial growth factor (VEGF) antibodies. Proteinuria is a risk factor for renal dysfunction and cardiovascular complications in patients with chronic kidney disease. However, the association between anti-VEGF antibody-induced proteinuria and renal dysfunction or cardiovascular complications remains unclear. Methods This retrospective, observational study included patients with cancer that were treated with bevacizumab (BV) at Kyoto University Hospital (Kyoto, Japan) between January 2006 and March 2018. Adverse event rates were compared between patients who developed qualitative ≥ 2 + proteinuria and those who developed 
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-024-02474-7